Translation of "Multiorganversagen" in English

Chao Yao-dong died of multiple organ dysfunction syndrome on August 20, 2008, at the age of 92.

In many cases, however, cerebral oedema, kidney failure and finally multiple organ failure also occur.

Characteristically, liver failure is followed by multiple organ failure.

The main concern for the next few days will be multisystem organ failure.

The mortality rate of intensive care patients with multi-organ failure is still very high.

This condition can lead to multiple organ dysfunction.

What does "scalable support for multi-organ failure" mean?

The disease will finally cause pareses, coma and multiple organ failure.

The end point is multi-organ failure.

Hepatic veno-occlusive disease occurred in one patient, who died of GVHD and multi-organ failure.

These infections may lead to septic shock, respiratory failure, renal failure, and/or multi-organ failure.

The main symptoms are fever, diarrhoea, vomiting and impaired coagulation, leading to multiple organ failure and shock.

Postnatal development of a severe heart insufficiency and multi organ failure, which was the reason why the child subsequently died.

12 events (heart failure, myocardial infarction, atrial fibrillation), pulmonary oedema, multi-organ failure, tumour lysis syndrome, cytokine release syndrome, renal failure, and respiratory failure were reported at lower or unknown frequencies.

An overdose of 10,000 mg (total dose in a single cycle, over 5 days) was taken by one patient and the adverse reactions reported were pancytopenia, pyrexia, multi- organ failure and death.

MOD or vasopressor dependent septic shock) when treated within a strictly defined time window, to assert the benefit/ risk profile of Xigris .”

The most frequently reported serious adverse events were pyrexia (11.4%), febrile neutropenia (11.4%), cytokine release syndrome (5.7%), sepsis (4.3%), device-related infection (4.3%), overdose (4.3%), convulsion (2.9%), respiratory failure (2.9%), hypoxia (2.9%), pneumonia (2.9%), and multi-organ failure (2.9%).

Therefore the MAH has committed to performing a placebo-controlled study in patients (who were either on low-dose prophylactic heparin or not receiving any thrombosis prophylaxis) with severe sepsis and documented organ failure (e.g. MOD or vasopressor dependent septic shock) when treated within a strictly defined time window, to assert the benefit/risk profile of Xigris.”

Various adverse events, such as hyperosmolality, lactic acidosis; renal dysfunction (acute tubular necrosis), acute renal failure; cardiotoxicity (arrhythmia, hypotension); central nervous system disorders (depression, coma, seizures); respiratory depression, dyspnoea; liver dysfunction; haemolytic reaction (intravascular haemolysis) and haemoglobinuria; or multisystem organ dysfunction, have been reported with high doses or prolonged use of propylene glycol.

Of these 76 reports, 67 (88.2%) cases reported pulmonary embolism with or without reported DVT or unspecified thrombosis, 8 (10.5%) reports described cerebral events, and 1 (1.3%) reported events of dyspnoea, disseminated intravascular coagulation and circulatory disorder in context of multi-organ failure, acute hepatic failure, coma hepatic, bone marrow failure, fungal sepsis, pneumonia and histiocytosis haematophagic in a female patient with condition of alcohol abuse, acute myeloid leukaemia, polychemotherapy and antibiotics therapy.

Fatal events other than those listed in section 4.4 above or section 4.8 below that were considered possibly related to SUTENT drug included multi-system organ failure, disseminated intravascular coagulation, peritoneal haemorrhage, rhabdomyolysis, cerebrovascular accident, dehydration, adrenal insufficiency, renal failure, respiratory failure, pleural effusion, pneumothorax, shock, and sudden death.

Some of these infections (e.g. pneumonia) have been severe (e.g. leading to sepsis, or respiratory or multi-organ failure) and have had fatal outcomes (see section 4.8).

They were often the result of a combination of events including pancytopenia, febrile neutropenia, some of them with sepsis, hepatic involvement, renal or multiorgan failure and rhabdomyolysis.

Exacerbations of pre-existing cardiac conditions such as angina pectoris or congestive heart failure or severe cardiac disorders (heart failure, myocardial infarction, atrial fibrillation), pulmonary oedema, multi-organ failure, tumour lysis syndrome, cytokine release syndrome, renal failure, and respiratory failure were reported at lower or unknown frequencies.

The most frequent (? 1%) adverse reactions that led to permanent discontinuation in monotherapy studies were infection, haemorrhage, multi-organ failure, and VOD.